Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (22283)	6/16/1998 9:00:00 AM
From: Sleepman	Read Replies (2) \| Respond to of 32384

I might be wrong, but I thought that there was some evidence that Panretin was active in psoriasis. I know that retinoids in general are, but in a search of medline, I found no references to it trial in psoriasis. Perhaps Henry could shed some light on the issue. But generally, I think that your analysis of why they pursued the KS indication is right on. Remember, when they started the process, KS was still fairly common in the AIDS population. Protease inhibitors were not out yet. Even though the target population for the initial indication is small, I still think that it is worth obtaining approval for the above mentioned reasons as well as a proof of concept thing. Happy investing. Dan